Interleukin 28B genetic polymorphism and hepatitis B virus infection

doi:10.3748/wjg.v20.i34.12026

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 34

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6045)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

387

WORD

281

HTML

3041

Tables (1-1)

112

Sum=3821

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1190

Download

1034

Sum=2224

Sep 14, 2014 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Sep 14, 2014; 20(34): 12026-12030
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12026

Interleukin 28B genetic polymorphism and hepatitis B virus infection

Toru Takahashi

Toru Takahashi, Division of Gastroenterology and Hepatology, Uonuma Hospital, Ojiyashi, Niigata 947-0028, Japan

Author contributions: Takahashi T solely contributed to this paper.

Correspondence to: Toru Takahashi, MD, PhD, Director, Division of Gastroenterology and Hepatology, Uonuma Hospital, 4-1-38 Jonai, Ojiyashi, Niigata 947-0028, Japan. torutoru@uonumahosp.jp

Telephone: +81-25-8832870 Fax: +81-25-8834789

Received: October 27, 2013
Revised: January 24, 2014
Accepted: April 8, 2014
Published online: September 14, 2014

Abstract

Interleukin (IL) 28B genetic polymorphism is significantly associated with the sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α (PEG-IFN) plus ribavirin and with spontaneous hepatitis C virus clearance. However, a consensus on the relationship between IL28B genetic polymorphism and the favorable outcome of chronic hepatitis B virus infection defined by hepatitis B e antigen seroconversion, and/or hepatitis B surface antigen seroclearance in patients treated with interferon or PEG-IFN has not been reached. Several reports failed to show a positive association, while some studies demonstrated a positive association in certain subject settings. More prospective studies including large cohorts are needed to determine the possible association between IL28B genetic polymorphism and the outcome of interferon or PEG-IFN treatment for chronic hepatitis B.

Keywords: Interleukin 28B, Polymorphism, Hepatitis B virus, Interferon, Pegylated interferon

Core tip: An association between interleukin (IL) 28B genetic polymorphism and sustained virological response rate in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin or spontaneous hepatitis C virus clearance has been established. However, the association between IL28B genetic polymorphism and hepatitis B virus infection remains unclear. We discuss this topic and summarize the available clinical data.